Multimeric FHR4 immunoconjugate‐mediated AP activation should therefore further potentiate the anti‐tumour response via complement receptors on different cell types (macrophages, NK cells), resulting in enhanced CDCC or CDCP and the recruitment and/or activation of effector cells. This evidence concerns the gene DHCR7-DT and neoplasm.